WallStSmart

Applovin Corp (APP)vsHaoxi Health Technology Limited Class A Ordinary Shares (HAO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Applovin Corp generates 14344% more annual revenue ($6.16B vs $42.68M). APP leads profitability with a 64.3% profit margin vs -6.5%. APP earns a higher WallStSmart Score of 76/100 (B+).

APP

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 3.7Quality: 8.0
Piotroski: 6/9Altman Z: 3.74

HAO

Hold

49

out of 100

Grade: D+

Growth: 8.7Profit: 2.0Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 5.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APP6 strengths · Avg: 10.0/10
Market CapQuality
$203.46B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
167.7%10/10

Every $100 of equity generates 168 in profit

Profit MarginProfitability
64.3%10/10

Keeps 64 of every $100 in revenue as profit

Operating MarginProfitability
78.1%10/10

Strong operational efficiency at 78.1%

Revenue GrowthGrowth
59.0%10/10

Revenue surging 59.0% year-over-year

EPS GrowthGrowth
113.1%10/10

Earnings expanding 113.1% YoY

HAO5 strengths · Avg: 9.8/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

EPS GrowthGrowth
172.7%10/10

Earnings expanding 172.7% YoY

Altman Z-ScoreHealth
5.8010/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

APP4 concerns · Avg: 2.8/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Debt/EquityHealth
1.493/10

Elevated debt levels

P/E RatioValuation
52.6x2/10

Premium valuation, high expectations priced in

Price/BookValuation
79.3x2/10

Trading at 79.3x book value

HAO4 concerns · Avg: 2.0/10
Market CapQuality
$1.97M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-15.5%2/10

ROE of -15.5% — below average capital efficiency

Free Cash FlowQuality
$-2.27M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-6.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : APP

The strongest argument for APP centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 64.3% and operating margin at 78.1%. Revenue growth of 59.0% demonstrates continued momentum.

Bull Case : HAO

The strongest argument for HAO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 41.2% demonstrates continued momentum.

Bear Case : APP

The primary concerns for APP are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 52.6x leaves little room for execution misses.

Bear Case : HAO

The primary concerns for HAO are Market Cap, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

APP profiles as a growth stock while HAO is a hypergrowth play — different risk/reward profiles.

APP carries more volatility with a beta of 2.37 — expect wider price swings.

APP is growing revenue faster at 59.0% — sustainability is the question.

APP generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

APP scores higher overall (76/100 vs 49/100), backed by strong 64.3% margins and 59.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Applovin Corp

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

AppLovin Corporation is committed to creating a software-based platform for mobile application developers to improve the marketing and monetization of their applications globally. The company is headquartered in Palo Alto, California.

Visit Website →

Haoxi Health Technology Limited Class A Ordinary Shares

COMMUNICATION SERVICES · ADVERTISING AGENCIES · USA

Haoxi Health Technology Limited Class A Ordinary Shares is a pioneering force in the health technology sector, focused on revolutionizing healthcare delivery through innovative solutions. Utilizing advanced technologies, including artificial intelligence and data analytics, the company significantly improves diagnostic accuracy, treatment efficiency, and patient management. With a robust commitment to research and development, Haoxi is well-positioned to capitalize on emerging trends in healthcare technology, presenting considerable growth opportunities for institutional investors looking to engage in this dynamic market.

Want to dig deeper into these stocks?